Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of spanish multiple sclerosis patients treated with natalizumab

Journal of Neuroimmune Pharmacology

Volumn 8, Issue 5, 2013, Pages 1277-1286

  Dominguez Mozo, Maria Inmaculada ^a   Garcia Montojo, Marta ^a   De Las Heras, Virginia ^a   Garcia Martinez, Angel ^a   Arias Leal, Ana María ^a   Casanova, Ignacio ^a   Arroyo, Rafael ^a   Alvarez Lafuente, Roberto ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Anti JCV antibodies; JC virus; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

AZATHIOPRINE; MITOXANTRONE; NATALIZUMAB; VIRUS ANTIBODY; VIRUS DNA;

ADULT; AGE; ANTIBODY DETECTION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; SEROPREVALENCE; SERUM; URINE; VIRUS LOAD;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; CROSS-SECTIONAL STUDIES; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; JC VIRUS; LEUKOCYTES, MONONUCLEAR; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MULTIPLE SCLEROSIS; POLYOMAVIRUS INFECTIONS; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 84891373461     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-013-9496-y     Document Type: Article

References (22)

1. Agostini HT, Ryschkewitsch CF, Stoner GL (1996) Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol 34:159-164
2. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870-1880
3. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361:1067-1074
4. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199:837-846
5. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295-303
6. Jilek S, Jaquiery E, Hirsch HH, Lysandropoulos A, Canales M, Guignard L, Schluep M, Pantaleo G, Du Pasquier RA (2010) Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 9:264-272
7. Kitamura T, Aso Y, Kuniyoshi N, Hara K, Yogo Y (1990) High incidence of urinary JC virus excretion in nonimmunosuppressed older patients. J Infect Dis 161:1128-1133
8. Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, Miller E (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71:115-123
9. Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palu G, Uccelli A, Mancardi GL, Varnier OE (2012) Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J Neuroimmune Pharmacol 7:665-672
10. Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M (2013) A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 57:141-146
11. Ling PD, Lednicky JA, Keitel WA, Poston DG, White ZS, Peng R, Liu Z, Mehta SK, Pierson DL, Rooney CM, Vilchez RA, Smith EO, Butel JS (2003) The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis 187:1571-1580
12. Major EO (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61:35-47
13. Mancuso R, Saresella M, Hernis A, Marventano I, Ricci C, Agostini S, Rovaris M, Caputo D, Clerici M (2012) JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients. J Transl Med 10:248
14. Matos A, Duque V, Beato S, da Silva JP, Major E, Melico-Silvestre A (2010) Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol 82:494-504
15. Perkins MR, Ryschkewitsch C, Liebner JC, Monaco MC, Himelfarb D, Ireland S, Roque A, Edward HL, Jensen PN, Remington G, Abraham T, Abraham J, Greenberg B, Kaufman C, Laganke C, Monson NL, Xu X, Frohman E, Major EO, Douek DC (2012) Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS Pathog 8:e1003014
16. Reid CE, Li H, Sur G, Carmillo P, Bushnell S, Tizard R, McAuliffe M, Tonkin C, Simon K, Goelz S, Cinque P, Gorelik L, Carulli JP (2011) Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis 204:237-244
17. Rinaldi L, Rinaldi F, Perini P, Calabrese M, Seppi D, Grossi P, Mattisi I, Barzon L, Mengoli C, Sanzari M, Palu G, Gallo P (2010) No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study. J Neurol Neurosurg Psychiatry 81:1345-1350
18. Rossi A, Delbue S, Mazziotti R, Valli M, Borghi E, Mancuso R, Calvo MG, Ferrante P (2007) Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects. J Med Virol 79:408-412
19. Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, Goelz E (2010) Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 68:304-310
20. Sadiq SA, Puccio LM, Brydon EW (2010) JCV detection in multiple sclerosis patients treated with natalizumab. J Neurol 257:954-958
21. Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A (2012) Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 78:1736-1742
22. Watzinger F, Suda M, Preuner S, Baumgartinger R, Ebner K, Baskova L, Niesters HG, Lawitschka A, Lion T (2004) Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients. J Clin Microbiol 42:5189-5198